Journal of Clinical Investigation · 1997 · 90 citations · 48 references
Life SciencesCell BiologyImmunologyAutoimmunityImmunotherapyRheumatologyAutoimmune DiseasesCell-mediated ImmunityEffector T Cell FunctionMultiple SclerosisRheumatoid ArthritisT Cell BiologyCd4 Positive T CellsCd4 T Cell ActivationCd4 T-cell DepletionMonoclonal Antibody TherapeuticsMultiple Sclerosis ImmunopathologyMultiple Sclerosis TherapyNaive T CellsT Cell-based Immunotherapy
CD4(pos) TH1 T cells are considered to play a central role in a number of human autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis. Experimental treatment protocols aimed at selectively eliminating CD4(pos) T cells thus far have yielded disappointing clinical results. Here we analyzed phenotype and function of circulating T cells in multiple sclerosis patients treated with the chimeric CD4 mAb cM-T412 in a randomized, double-blind, placebo-controlled, magnetic resonance imaging-monitored phase II trial. Treatment resulted in a long-lasting depletion of CD4(pos) T cells but did not affect CD8(pos) T cell numbers. Analysis of CD4(pos) subpopulations showed that unprimed, CD45RA(pos)/R0(neg) lymphocytes were approximately three times more sensitive to the mAb than primed, CD45RA(neg)/R0(pos) T cells. Notably, within the CD45RA(pos) subset, T cells with phenotypic evidence of prior activation, i.e., expressing Fas, were relatively insensitive to cM-T412, compared with Fas(neg) cells. Remarkably, while a decrease in the number of IL-4-producing T helper 2 (TH2)-type cells in the anti-CD4 treated group was observed, numbers of IFN-gamma-producing T helper 1 (TH1)-type cells remained stable, resulting in a significant increase in the TH1/TH2 ratio. Our data show that treatment with depleting CD4 mAb does not eliminate the cells most strongly involved in the disease process, i.e., primed, IFN-gamma-producing TH1-type cells, and may therefore give an explanation for the lack of beneficial clinical effects of depleting CD4 mAb in human chronic autoimmune disease.
48
Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1
Jerry H. Brown, Theodore S. Jardetzky, Joan C. Gorga et al. · Nature · 1993 · 2.4K citations
Human TH1 and TH2 subsets: doubt no more
S Romagnani · Immunology Today · 1991 · 1.1K citations
Detection of intracellular cytokines by flow cytometry
Thomas Jung, Christoph Heusser, Christine Neumann et al. · Journal of Immunological Methods · 1993 · 988 citations